Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
UNIVERSITAT HEIDELBERG is currently managing 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 5 distinct examiners. This indicates a high level of examiner diversity, as each pending matter is handled by a different individual. The portfolio's activity spans 4 distinct art units, showing a broad technical distribution within its primary technology area.
The busiest examiner for the university is SANGHERA, STEVEN G.S. This examiner is responsible for 1 busiest examiner pending office action. Given that there are 5 pending office actions and 5 distinct examiners, SANGHERA, STEVEN G.S. manages exactly one of the current pending matters. The distribution across 4 distinct art units suggests that while the examiners are unique, some overlap exists in the technical units reviewing these 5 pending office actions. Practitioners should prepare for varied examination styles across the 4 distinct art units involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (25%) |
| §101 + other | 2 (50%) |
| Double-patenting + other | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SANGHERA, STEVEN G.S. | 1 | 30.8% | +30.4% |
| HU, ANN M | 1 | 67.8% | +21.6% |
| SCHWECHTER, BRANDON ROSS | 1 | 0.0% | +0.0% |
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18692301 | SAMPLING INTERVAL ADJUSTED CLASSIFICATION TOOL | SANGHERA, STEVEN G.S. | — |
| 18687769 | PERIVASCULAR IMPLANT | HU, ANN M | — |
| 18552115 | ANTIGEN REACTIVE T-CELL RECEPTORS | SCHWECHTER, BRANDON ROSS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18692301 | SAMPLING INTERVAL ADJUSTED CLASSIFICATION TOOL | SANGHERA, STEVEN G.S. | — |
| 18687769 | PERIVASCULAR IMPLANT | HU, ANN M | — |
| 17767880 | CONJUGATE COMPOUNDS FOR PREVENTING AND/OR TREATING HBV AND/OR HDV INFECTIONS, LIVER DISEASES AND FOR TARGETING NTCP | REYNOLDS, FRED H | — |
| Art Unit | Apps |
|---|---|
| 3684 | 1 |
| 1681 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18692301 | SAMPLING INTERVAL ADJUSTED CLASSIFICATION TOOL | SANGHERA, STEVEN G.S. | 3684 | §101 | Final Rejection | — | Pending | Mar 14, 2024 |
| 18687769 | PERIVASCULAR IMPLANT | HU, ANN M | — | §101§102§103§112 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18552115 | ANTIGEN REACTIVE T-CELL RECEPTORS | SCHWECHTER, BRANDON ROSS | 1681 | §101§102§112 | Non-Final OA | — | Pending | Sep 22, 2023 |
| 17767880 | CONJUGATE COMPOUNDS FOR PREVENTING AND/OR TREATING HBV AND/OR HDV INFECTIONS, LIVER DISEASES AND FOR TARGETING NTCP | REYNOLDS, FRED H | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Apr 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial